Compare · COSM vs CVET
COSM vs CVET
Side-by-side comparison of Cosmos Health Inc. (COSM) and Covetrus Inc. (CVET): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COSM and CVET operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- CVET is the larger of the two at $2.42B, about 112.6x COSM ($21.5M).
- COSM has hit the wire 4 times in the past 4 weeks while CVET has been quiet.
- CVET has more recent analyst coverage (8 ratings vs 0 for COSM).
- Company
- Cosmos Health Inc.
- Covetrus Inc.
- Price
- $0.22+3.81%
- $21.00+0.24%
- Market cap
- $21.5M
- $2.42B
- 1M return
- +11.60%
- -
- 1Y return
- -98.70%
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 4
- 0
- Recent ratings
- 0
- 8
Cosmos Health Inc.
Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.
Covetrus Inc.
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.
Latest COSM
- Cosmos Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway
- SEC Form 10-Q filed by Cosmos Health Inc.
- SEC Form NT 10-Q filed by Cosmos Health Inc.
- Chief Executive Officer Siokas Grigorios bought $70,000 worth of shares (349,825 units at $0.20), increasing direct ownership by 2% to 14,597,917 units (SEC Form 4)
- Chief Financial Officer Terzis Georgios was granted 328,407 shares, increasing direct ownership by 15% to 2,563,805 units (SEC Form 4)
- Chief Executive Officer Siokas Grigorios bought $140,000 worth of shares (766,284 units at $0.18), increasing direct ownership by 6% to 14,248,092 units (SEC Form 4)
- Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels
- SEC Form RW filed by Cosmos Health Inc.
- Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units
Latest CVET
- Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer
- Key Cannabis Exec Changes You Need To Know About: Leafly's New CCO, Glass House's New Appointment & More
- SEC Form 15-12G filed by Covetrus Inc.
- Westlake Set to Join S&P MidCap 400; MillerKnoll to Join S&P SmallCap 600
- Westlake Set To Join S&P MidCap 400, Replacing MillerKnoll; MillerKnoll To Replace Coventrus In S&P SmallCap 600
- SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)
- SEC Form 4: Cd&R Investment Associates Ix, Ltd. disposed of 33,670,541 shares
- SEC Form S-8 POS filed by Covetrus Inc.
- SEC Form SC 13E3/A filed by Covetrus Inc. (Amendment)
- Covetrus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits